Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds
can act as selective modulators of CRF receptors. The
5-substituted-2-arylpyrazine compounds provided herein are useful in the
treatment of a number of CNS and periphereal disorders, particularly
stress, anxiety, depression, cardiovascular disorders, and eating
disorders. Methods of treatment of such disorders and well as packaged
pharmaceutical compositions are also provided. Compounds provided are
also useful as probes for the localization of CRF receptors and as
standards in assays for CRF receptor binding. Methods of using the
compounds in receptor localization studies are given.